Fresenius Medical Care appoints Shervin J. Korangy as new CEO and board chair
Fresenius Medical Care announced that Shervin J. Korangy will assume the roles of chief executive officer and chairman of the management board on 12 October 2026, replacing Helen Giza. Korangy, 51, previously led BVI Medical from 2017 until early 2026 and has served on Fresenius’ supervisory board since 2023. The transition follows the completion of the FME25+ transformation that cut the cost base by roughly EUR 1.2 billion.
Why it matters
The company’s shares fell about 7% after the news, reflecting market concern over the leadership change. The new CEO is expected to drive further growth and innovation, but short‑term price pressure may affect investors holding the ADR (FMS).
Key facts
- 1Shervin J. Korangy will become CEO and chair of the management board on 12 October 2026. prnewswire.com
- 2He succeeds Helen Giza, who led the firm for four years as CEO after three years as CFO. prnewswire.com
- 3Under Giza’s tenure the FME25+ program reduced the cost base by around EUR 1.2 billion. prnewswire.com
- 4Fresenius Medical Care operates 3,513 dialysis clinics and treats roughly 290,000 patients worldwide. investing.com
- 5Korangy was president and CEO of BVI Medical from 2017 to 2026, expanding the business to nearly 90 countries. finance.yahoo.com
- 6He left BVI Medical in January 2026 and then served as a senior adviser to BVI and TPG Capital. finance.yahoo.com
Summary written by AlphAI from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.